DP
LRMR icon

Diadema Partners’s Larimar Therapeutics LRMR Stock Holding History

Diadema Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,900
Closed -$65.4K – 137
2024
Q4 		$65.4K Buy
+16,900
New +$112K 0.03% 96

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Diadema Partners's LRMR Position: Q2 2026 in Review

Diadema Partners reduced its Larimar Therapeutics (LRMR) stake by 12% in Q2 2026, selling an estimated $79.4K and leaving 146,637 shares worth $447K. The position accounts for 0.06% of the portfolio, ranked #119.

Diadema Partners first reported a position in LRMR in Q4 2024 and has held it in 3 quarters since. The position peaked at $750K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Diadema Partners held 146,637 shares of Larimar Therapeutics worth $447K as of Q2 2026.
  • Diadema Partners sold 20,000 Larimar Therapeutics shares in Q2 2026, an estimated $79.4K.
  • Larimar Therapeutics made up 0.06% of Diadema Partners's portfolio in Q2 2026, its #119 holding.
  • Diadema Partners first reported a position in Larimar Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Diadema Partners's Larimar Therapeutics position peaked at $750K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.